Dr. Fouad A. Abuzeid, MD

Dr. Abuzeid practices at Martin Health Physician Group - HOPD in Port Saint Lucie, Florida.

Dr. Abuzeid's NPI, 1255793642, was assigned on March 24, 2016. Dr. Abuzeid graduated from American University of the Caribbean School of Medicine in 2014. Dr. Abuzeid holds Florida license ME145416.

Dr. Abuzeid's primary practice is Martin Health Physician Group - HOPD, at 10000 Sw Innovation Way, Port Saint Lucie, FL 34987.

Dr. Abuzeid's primary practice is Martin Health Physician Group - HOPD in Port Saint Lucie, Florida. Dr. Abuzeid is also affiliated with Cleveland Clinic Martin North Hospital. The medical group on file is Cleveland Clinic. Dmand AI also links Dr. Abuzeid to 1 more group practice or clinic, named with a free account. Dr. Abuzeid's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Abuzeid practices, 3 sites in all. Vendor and product names are available with a free account.

Neurocritical care is Dr. Abuzeid's primary specialty in the NPI Registry, under taxonomy code 2084A2900X. Dmand AI has Dr. Abuzeid's licenses on file in 2 states: Florida and Mississippi.

Dmand AI lists acute mini-stroke (TIA), cerebrovascular disease, epilepsy and migraine and chronic headache among the conditions Dr. Abuzeid treats.

CMS data shows 725 Medicare services from Dr. Abuzeid across 5 procedure codes in 2024, for 380 Medicare patients. Medicare paid $97,616 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 380 Medicare patients who saw Dr. Abuzeid in 2024. The largest group is 75 to 84, with 164 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 2.29, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Abuzeid's median patient age at 68, with 47% women.

In 2020, Dr. Abuzeid wrote 13 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $892 in total drug cost. In 2019, CMS named 18 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Abuzeid for performance year 2024, reported through an alternative payment model (APM). Dr. Abuzeid accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 21 general payments to Dr. Abuzeid from 10 drug and device companies from 2017 to 2023. Food and beverage make up the largest share, 88% of the total. Sanofi and Genzyme US Companies paid the most, $123.

Dr. Abuzeid graduated from American University of the Caribbean School of Medicine in 2014.